We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK lags far behind other industrialized countries in providing patients access to the latest medicines, a situation that is caused by overly zealous national and local healthcare funding schemes, asserts a new report from a British pharmaceutical trade group. Read More
The FDA yesterday finalized the first of four guidances that govern how drugmakers scale up production of a drug once it’s approved, the first revision to the guidances since the late 1990s. Read More
Manufacturers of fixed dose combination products that are less than four years old should confirm with India’s drug pricing authority that the products have been approved and are not deemed prohibited under Indian drug law. Read More
The FDA has rejected Teva’s seventh citizen petition calling for the agency to boost its scrutiny of any ANDA seeking to make a generic version of the Israeli firm’s blockbuster multiple sclerosis drug Copaxone. Read More
A pan-European health technology assessment body has recommended that EU cost-effectiveness evaluators compare new pharmaceuticals against the most relevant standards of care, in a new framework to harmonize different member states’ individual guidelines on making coverage decisions. Read More
The European Medicines Agency last week approved Boehringer Ingelheim’s lung cancer drug Vargatef for treating non-small cell lung adenocarcinomas. Read More
UK healthcare cost evaluators affirmed their earlier coverage recommendation of Alexion’s rare blood disease drug Soliris, but still expressed concerns over the therapy’s high costs. Read More
Manufacturers of prescription and over-the-counter drugs containing acetaminophen should warn patients about the risk of serious skin reactions, according to an FDA draft guidance. Read More
The European Commission has approved Janssen’s HIV combination drug Rezolsta, which combines the company’s protease inhibitor Prezista and Gilead Sciences’ pharmacokinetic enhancer Tybost. Read More
The FDA has added a warning about risks of a rare brain infection associated with Biogen Idec’s multiple sclerosis drug Tecfidera, after the first confirmed death of a patient taking the drug. Read More